H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $1.30.
According to TipRanks, Pantginis is a 2-star analyst with an average return of 0.0% and a 37.27% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Clene, Cytokinetics, and VYNE Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Armata Pharmaceuticals with a $8.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.92 and a one-year low of $0.83. Currently, Armata Pharmaceuticals has an average volume of 13.03K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Read More on ARMP:
